55 interventions.
ApoB (Apolipoprotein B)
One of the few longevity-community favorites that is genuinely well-founded: causality is established by genetics and trials, and ApoB meaningfully improves risk assessment over LDL-C, especially in metabolically abnormal people. Not hype. The main gap is that guideline adoption and outcome-defined ApoB targets are still catching up to the mechanistic case.
GLP-1 Receptor Agonists (Semaglutide, Tirzepatide)
Genuinely transformative cardiometabolic drugs with real mortality-relevant benefit in people with excess weight, but they are not validated longevity agents, and muscle loss plus lack of aging-specific outcome data temper the 'anti-aging miracle' framing. Powerful for the right person, not a geroprotector for the lean and healthy.
Mediterranean Diet
One of the very few longevity interventions with randomized hard-outcome evidence, not just biomarkers. It is genuinely evidence-based and low-risk. The main caveat is that PREDIMED tested it against a low-fat comparator in a Spanish high-risk population, so effect sizes may not transfer identically everywhere.
Resistance Training
One of the most underrated, best-evidenced longevity interventions. Preserving muscle and strength directly protects against the frailty-disability-death cascade. No supplement or drug rivals it for maintaining functional independence, yet it gets a fraction of the attention of unproven therapies.
SGLT2 Inhibitors (Canagliflozin, Empagliflozin, Dapagliflozin)
Real, hard-endpoint mortality benefit in sick populations (heart/kidney disease) and a striking male-mouse lifespan result, but the sex-specific animal effect and lack of any healthy-human aging trial mean the leap to 'longevity drug for the well' is unearned.
Statins (in a Longevity Context)
Genuinely life-saving for cardiovascular risk, and preventing the #1 killer buys years, but that is targeted disease prevention, not aging modulation. Calling statins a 'longevity drug' conflates two different things: they lengthen life by stopping heart attacks, not by slowing the aging process.
Zone 2 & VO2max Cardio
VO2max is arguably the most powerful modifiable predictor of longevity, and improving it is unambiguously beneficial. The specific Zone-2 framing is popular and physiologically reasonable, but the mortality data are observational (fit people differ from unfit people) and no trial proves a Zone-2 label outperforms simply doing plenty of aerobic exercise plus some high intensity.
Caloric Restriction (CR)
The strongest evidence base of any longevity intervention for slowing biological-age surrogates, but no human trial shows it extends lifespan, primate data are mixed, and severe long-term adherence is unrealistic for most. Diet composition may matter as much as calorie count.
Coenzyme Q10 / Ubiquinol
One intriguing cardiovascular-mortality RCT (confounded by co-administered selenium) is the strongest evidence, and it does not generalize to healthy people or to aging broadly. Reasonable for specific cardiac contexts and statin-associated myalgia; oversold as a general anti-aging antioxidant.
Collagen Peptides
Decent evidence for skin and joint cosmesis, largely from company-funded trials, and essentially nothing about actual aging biology or lifespan. It is a targeted beauty/joint supplement wearing a longevity costume. Fine if you want the skin effect; not a geroprotector.
Creatine Monohydrate
Refreshingly, the evidence here is real and boring: creatine plus lifting reliably builds strength in older adults, and strength predicts survival. It is not a direct lifespan pill, but it is one of the best-supported, safest, cheapest tools for healthspan via muscle. Under-hyped relative to its evidence.
Fasting-Mimicking Diet (FMD)
The most rigorously formalized periodic-fasting protocol with real (if surrogate) RCT data, but benefits look comparable to any effective calorie reduction, endpoints are all biomarkers, and the leading investigator commercializes the product. Promising, not proven to extend human life.
GlyNAC (Glycine + N-Acetylcysteine)
The reported effect sizes are almost too good, and that is exactly why skepticism is warranted: small, mostly single-lab, partly open-label trials showing improvement across nearly every hallmark at once. Biologically plausible and low-risk, but it needs large independent replication before the sweeping claims can be trusted.
Inflammatory Markers (hsCRP)
A validated, inexpensive marker of the inflammaging that underlies much age-related disease, with genuine causal backing from CANTOS. Its limitation is nonspecificity: a single high hsCRP can reflect a cold or extra body fat rather than aging, so it is a trend tool, not a precise aging readout.
NAD+ Precursors (NMN & Nicotinamide Riboside)
The classic 'raises a biomarker, therefore anti-aging' story. Yes, they raise NAD+. No, that has not translated into demonstrated healthspan or lifespan benefit in humans despite dozens of trials. One of the most over-marketed categories relative to its clinical evidence.
Protein Intake & Leucine
The fitness world's 'more protein always' and the longevity world's 'restrict protein' are both oversimplified. Protein is essential to prevent sarcopenia (a top functional-mortality driver) in older adults, but blanket high intake in midlife is not clearly optimal for longevity. Source and age matter.
Stress Reduction & Meditation
Chronic stress genuinely accelerates biological aging, and stress reduction improves wellbeing and modestly improves BP and inflammation. But the specific 'meditation lengthens your telomeres and extends life' narrative rests on small, inconsistent, bias-prone studies with no outcome data. Worth doing for stress and quality of life; not a validated anti-aging therapy.
Sulforaphane
A legitimate NRF2 activator with real (non-aging) human trial signals, but zero evidence it slows aging or extends healthspan. 'Eat your cruciferous vegetables' is sound; 'sulforaphane is a proven longevity compound' is not.
Time-Restricted Eating / Intermittent Fasting
A convenient way to cut calories with modest metabolic upside, but it is not magic: rigorous RCTs show it rarely beats plain calorie restriction, muscle loss is a real risk, and there is zero human longevity outcome data. Meal timing (earlier) probably matters more than the fasting label.
Urolithin A
One of the few longevity supplements with multiple positive, properly controlled human RCTs, though the benefits are modest and about muscle/mitochondrial function, not proven lifespan. Reasonable evidence for a real (if small) healthspan effect. Less hype gap than most, but do not expect it to extend life.
Blue Zones Practices
The advice (eat plants, move, connect, have purpose) is sound and independently evidence-based, but the Blue Zones branding rests on demographic data now credibly challenged for record-keeping fraud and age exaggeration. Follow the habits; distrust the mythology and the commercial ecosystem built on it.
Cold Exposure
Genuine acute effects on brown fat and catecholamines, and many feel great doing it, but longevity claims are speculative with no outcome data, and it can actively undermine muscle-building. Best viewed as a mood/resilience practice, not a proven aging intervention.
Composite Biological Age Blood Tests (PhenoAge)
A cheap, well-validated way to summarize routine labs into a mortality-predictive biological age, more accessible than epigenetic clocks. But it predicts risk; it does not prove that pushing the number down extends life, and the DTC market layers marketing and unvalidated variants on top of the sound core method.
Epigenetic Clocks (Horvath, GrimAge, DunedinPACE)
The best surrogate we have for biological aging and genuinely predictive of outcomes. But a clock reading is a prediction, not a proven modifiable target: no one has shown that lowering your GrimAge with a supplement makes you live longer. Treat them as research-grade risk indicators, not a scoreboard to game.
Frailty Index
One of the most clinically validated, decision-relevant measures of biological aging, quietly outperforming trendier tests, but it is most informative in older adults and is a status marker rather than something you directly 'lower.' Underused in longevity circles that prefer novel biomarkers over this robust standby.
Glucose Monitoring / CGM
Glucose control is unquestionably important for aging, and testing HbA1c/fasting glucose is standard good medicine. But strapping a CGM on a healthy person to chase flat curves is a wellness trend running well ahead of evidence: postprandial spikes are normal, devices are noisy, and no outcome data support it. Valuable for dysglycemia, oversold for the worried well.
Grip Strength
A remarkably powerful, dirt-cheap prognostic marker that outperforms blood pressure for mortality prediction. Its limitation is that it is a marker, not a lever: squeezing harder does nothing, but building total-body strength (which grip reflects) does. Excellent for risk stratification and monitoring.
Lithium (Low Dose)
Interesting invertebrate lifespan data and suggestive drinking-water epidemiology, but the mouse data showed healthspan-only (no lifespan) benefit and human evidence is purely correlational. A plausible hypothesis with no human aging trial. Not a validated intervention.
Metformin
The poster child of 'geroprotector' hype, but the human longevity case rests on confounded observational data, and the one clean signal in healthy people (blunted exercise benefit) cuts against it. Excellent diabetes drug; unproven and possibly counterproductive as a longevity supplement for metabolically healthy, fit adults.
Sauna / Heat Exposure
Plausible mechanism and striking cohort associations, but all major human data are observational from one sauna-cultured population, so causation is not established and confounding by healthy-user status is likely. A reasonable, low-risk adjunct, not a proven life-extender.
Sleep Optimization
Foundational and consistently underweighted next to flashier interventions. The 7-hour optimum is robust, but the U-shape means long sleep is often a marker of underlying illness rather than a cause. Sleep is a lever you must not neglect, though the mortality associations are observational and partly reverse-causal.
Social Connection
One of the largest and most reproducible non-biological predictors of longevity, and among the most neglected in a supplement-obsessed longevity market. Not a product to sell, so it gets little airtime despite an effect size rivaling smoking. Observational, but the evidence base is deep and coherent.
Spermidine
Strong and attractive preclinical autophagy story with supportive epidemiology, but the single well-controlled human cognition RCT was flat-out negative. Marketed on mouse and correlational data; the best human trial did not deliver. Promising nutrient, not a proven intervention.
VO2max Testing
Unlike many longevity biomarkers, VO2max is both a top-tier predictor and directly, provably improvable through exercise, making it one of the most actionable diagnostics available. The main caveat is that consumer-wearable VO2max estimates are only rough approximations of a lab CPET.
17-Alpha-Estradiol
A fascinating mechanistic tool that keeps working in the ITP, but with zero human data and a hard male-only sex bias, it is a research compound, not a supplement anyone should be taking. Interesting biology, not a therapy.
Acarbose
Genuinely impressive and reproducible in male mice, which is why the ITP takes it seriously, but the sex bias is a red flag and there is zero human longevity evidence. A reasonable, cheap, low-risk bet, not a proven human intervention.
Rapamycin (Sirolimus)
The best-validated geroprotector in animals and the most credible pharmaceutical bet, but the human evidence is still thin: one small underpowered RCT that missed its primary endpoints. 'Proven to extend human lifespan' is false. 'Most promising, still unproven, needs the hard trials' is the honest read.
Senolytics: Dasatinib + Quercetin (D+Q)
The senescent-cell-clearance concept is real and D+Q genuinely reduces senescent-cell burden in humans, which is a landmark. But translating that into hard clinical benefit has so far mostly failed or underwhelmed, and dasatinib's toxicity makes self-experimentation reckless. Promising mechanism, unproven therapy.
Taurine
Exploded from one 2023 Science paper into a viral 'anti-aging amino acid,' then the central biomarker claim (taurine declines with age) failed to replicate in a rigorous 2025 study. Cheap and safe, but the human longevity case is now genuinely in doubt. A vivid lesson in not building a supplement trend on a single unreplicated finding.
Alpha-Ketoglutarate (Calcium AKG)
The mouse morbidity-compression data is genuinely interesting, but the headline human claim ('8 years younger') comes from an uncontrolled retrospective methylation-clock analysis of a product sold by the study's backers, which is close to worthless as proof. Intriguing mechanism, marketing that vastly overstates the human evidence.
Fisetin
Marketed as a natural senolytic based almost entirely on one mouse study and cell screens, with essentially no positive human data and a real bioavailability problem. The enthusiasm outruns the evidence badly. Plausible, cheap, low-risk, but 'proven senolytic in people' is not true.
Hyperbaric Oxygen Therapy (HBOT)
A widely marketed 'age-reversal' therapy built on one small uncontrolled study of surrogate markers from a group that runs commercial clinics. The telomere findings are interesting but unreplicated and unlinked to any health outcome. Be skeptical of clinics charging tens of thousands citing this single paper as proof of rejuvenation.
Mitochondrial Transfer / Transplantation
Real, careful science exists for a narrow ischemia indication, but 'mitochondrial transplant to reverse aging' is essentially theoretical, with no human aging data and unsolved problems of delivery, persistence, and immunogenicity. Any consumer 'mitochondrial therapy' for aging is far ahead of the evidence.
Partial Reprogramming (Yamanaka Factors)
Scientifically the most exciting frontier in rejuvenation, and it has just crossed into humans: the FDA cleared the first OSK gene therapy in January 2026. But that trial is for an eye disease and has no results, mouse lifespan data is the only efficacy evidence, and the cancer risk is real. 'Proven to reverse human aging' is false; 'the frontier just opened its first human trial' is the honest read. Any clinic selling 'reprogramming' rejuvenation today is selling something unproven and potentially dangerous.
Thymus Regeneration (TRIIM)
A genuinely intriguing first human hint that epigenetic age might be reversible and the thymus regrown, widely publicized. But it is 9 people, no control group, and the reversal may reflect growth hormone/metformin rather than thymic rejuvenation. Growth hormone carries real risks. Await the controlled trial before believing the headline.
Aspirin (Low Dose)
A clear case where a large rigorous RCT settled it: for healthy older adults chasing longevity, daily aspirin is net-harmful (more bleeding, no survival benefit, a worrying mortality signal). Useful drug for the right cardiovascular indication, wrong drug for general 'anti-aging.'
Omega-3 Fatty Acids (EPA/DHA)
The definitive large RCT (VITAL) was essentially null for hard outcomes in the general population, and omega-3 did not even move telomere length. Benefit is real but confined to specific high-risk cardiovascular subgroups at high doses. As a broad longevity supplement, the evidence is underwhelming.
Resveratrol
The archetype of longevity hype collapsing under scrutiny: discredited primary mechanism, negative ITP lifespan results, disappointing human trials, and terrible bioavailability. If any single supplement should have exited the longevity conversation, it is this one. Marketing far outlived the science.
Vitamin D
A perfect example of correlation vs causation: low vitamin D tracks with bad health, but supplementing replete people did not cut mortality or cancer in the definitive RCT. The 2025 telomere finding is intriguing and worth following, but as of now the honest story is 'fix deficiency, do not expect miracles from extra.'
Epitalon (Epithalon)
Promoted in biohacker circles on the strength of unreplicated, low-quality single-lab studies, sold as an unregulated injectable. There is no credible independent human evidence it does anything for aging. This is at the far speculative end: high hype, minimal legitimate science, real sourcing risk.
Exosomes
A legitimate and promising research vehicle for cell-free signaling therapy that has been prematurely commercialized into unregulated IV, injected, and 'facial' exosome products sold for rejuvenation with zero efficacy evidence and documented infection harms drawing FDA warnings. The biology is real; the marketplace offerings are unproven and unsafe.
Gene Therapy (Follistatin, Telomerase/TERT)
Compelling mouse biology, but human 'evidence' consists of a founder's uncontrolled self-experiment and marketing by offshore biohacking ventures selling injections with no trials, no safety data, and a plausible cancer risk. Anyone offering follistatin or telomerase gene therapy for aging today is operating far outside validated medicine. Extreme skepticism warranted.
Plasma Dilution / Young Plasma
A vivid mouse phenomenon that spawned a predatory clinic industry selling young-blood infusions for thousands of dollars with zero human efficacy evidence, drawing an explicit FDA warning. The more interesting science (dilution/removal of bad factors) is still preclinical. Treat any young-plasma 'longevity' offering as a red-flag scam.
Stem Cell Therapies
A legitimate research area for specific diseases that has been aggressively hijacked by predatory clinics selling IV or injected 'stem cells' for anti-aging with no efficacy evidence and real, sometimes catastrophic, harms. Frontier, a site we also run, covers one example of that legitimate side: manufactured islet cells reversing type 1 diabetes in a first trial. There is no proven stem-cell therapy for aging itself. This is one of the highest-risk areas for consumer exploitation.
TA-65 / Telomerase Activators (Cycloastragenol)
Expensive, heavily marketed on the seductive telomere theory, with only small often-conflicted trials, an alternative (immune-cell-shift) explanation for its main claimed effect, no outcome data, and an unresolved cancer concern. High price, weak and contested evidence: among the poorer value propositions in this list.